{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:12:19Z","timestamp":1792735939193,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203077"],"award-info":[{"award-number":["203077"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203077"],"award-info":[{"award-number":["203077"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2016V-1649-MMVC"],"award-info":[{"award-number":["RIA2016V-1649-MMVC"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2016V-1649-MMVC"],"award-info":[{"award-number":["RIA2016V-1649-MMVC"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Two licensed vaccines block\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria sporozoites through anticircumsporozoite protein antibodies. In animal models, intradermal (ID) sporozoites are more readily blocked than intravenous sporozoites. We hypothesized that this complicates human studies, where infectious mosquito bites deliver a mixture of ID and venous sporozoites. Here, to test whether vaccine efficacy varies by route of inoculation, we undertook a phase 2b open, randomized controlled trial, recruiting healthy volunteers in Kenya for randomization to the circumsporozoite protein-based R21\/Matrix-M vaccine (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200938), thrombospondin-related adhesive protein fused to a multi-epitope string (ME-TRAP)-based vaccines (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924) or to control (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918). We enrolled 37 of these volunteers to controlled human malaria infection (CHMI) using ID or direct venous injection (DVI) of sporozoites, with PCR monitoring of parasitemia. Systemic and local postvaccination adverse events and systemic CHMI-related events were detected in 4.8%, 12.9% and 72.9% of volunteers, respectively, most commonly fever, headache and fatigue. No serious or severe adverse events were seen. Seven of 8 (88%) control volunteers and 11 of 12 (92%) ME-TRAP vaccinated volunteers, but none of the 12 R21 vaccinated volunteers receiving ID challenge met the prespecified treatment criteria for the primary endpoint. However, five of five R21 vaccinated volunteers receiving DVI sporozoites met the primary endpoint (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0005 by log rank across all groups). Secondary efficacy outcomes were similar; that is, R21 vaccinated volunteers receiving ID challenge did not meet any secondary endpoints, whereas volunteers for other groups met secondary endpoints between days 7 and 21 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0005,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0001,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0007 and\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0005 by log rank for time to parasitemia &gt;20, &gt;500, &gt;1,000 and &gt;10,000, respectively). R21\/Matrix-M was highly protective against CHMI using ID. inoculation of sporozoites, but not against DVI sporozoites. CHMI is used in clinical development to select efficacious vaccines and to define correlates of efficacy. Correlates of efficacy for antibodies to sporozoites should also be assessed by separate DVI and ID challenges. The study was registered with ClinicalTrials.gov (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03947190?term=NCT03947190&amp;rank=1\" ext-link-type=\"uri\">NCT03947190<\/jats:ext-link>\n                    ) and PACTR (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=15911\" ext-link-type=\"uri\">PACTR202108505632810<\/jats:ext-link>\n                    ).\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04107-6","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:02:29Z","timestamp":1767693749000},"page":"178-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-7128","authenticated-orcid":false,"given":"Melissa C.","family":"Kapulu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Orenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domtila","family":"Kimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kibwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Kibet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mutahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-2842","authenticated-orcid":false,"given":"Mehreen S.","family":"Datoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Musembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ngoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamisi","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellamaris","family":"Akinyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwaganyuma H.","family":"Mwatasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Nyamako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvias","family":"Keter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Gatheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Mutiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Musyoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidah","family":"Mwacharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ngetsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Mosobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnstone","family":"Makale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-0470","authenticated-orcid":false,"given":"Lynette I.","family":"Ochola-Oyier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-7879","authenticated-orcid":false,"given":"Fernando","family":"Ramos-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-5456","authenticated-orcid":false,"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-8905","authenticated-orcid":false,"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-9505","authenticated-orcid":false,"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-1414","authenticated-orcid":false,"given":"Mainga","family":"Hamaluba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-7549","authenticated-orcid":false,"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"4107_CR1","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"4107_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"4107_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","volume":"390","author":"K Kayentao","year":"2024","unstructured":"Kayentao, K. et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N. Engl. J. Med. 390, 1549\u20131559 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny, M. A. et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 387, 367\u2013375 (2016).","journal-title":"Lancet"},{"key":"4107_CR5","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"RTS,S Clinical Trials Partnership et al.","year":"2011","unstructured":"RTS,S Clinical Trials Partnership et al. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863\u20131875 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu, A. et al. Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children. N. Engl. J. Med. 374, 2519\u20132529 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR7","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.vaccine.2014.02.042","volume":"32","author":"JJ Campo","year":"2014","unstructured":"Campo, J. J. et al. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S\/AS02 in Mozambique. Vaccine 32, 2209\u20132216 (2014).","journal-title":"Vaccine"},{"key":"4107_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo, M. S. et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728\u20131736 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"4107_CR9","unstructured":"World Health Oragnization. Statistical Report, Malaria Vaccine Pilot Evaluation (MVPE), Analysis of Data to Month 46 (WHO, 2024); https:\/\/www.who.int\/publications\/m\/item\/statistical-report\u2013malaria-vaccine-pilot-evaluation-(mvpe)\u2013analysis-of-data-to-month-46"},{"key":"4107_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1086\/651025","volume":"201","author":"AI Olotu","year":"2010","unstructured":"Olotu, A. I., Fegan, G. & Bejon, P. Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults. J. Infect. Dis. 201, 970\u2013971 (2010).","journal-title":"J. Infect. Dis."},{"key":"4107_CR11","first-page":"337","volume":"445","author":"E Kibwana","year":"2024","unstructured":"Kibwana, E., Kapulu, M. & Bejon, P. Controlled human malaria infection studies in Africa\u2014past, present, and future. Curr. Top. Microbiol. Immunol. 445, 337\u2013365 (2024).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"4107_CR12","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1128\/IAI.01358-08","volume":"77","author":"P Bejon","year":"2009","unstructured":"Bejon, P. et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect. Immun. 77, 1917\u20131923 (2009).","journal-title":"Infect. Immun."},{"key":"4107_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337\u2013346 (2009).","journal-title":"J. Infect. Dis."},{"key":"4107_CR14","first-page":"100867","volume":"0","author":"N Venkatraman","year":"2024","unstructured":"Venkatraman, N. et al. R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18\u201345 years: an open-label, partially blinded, phase 1\u20132a controlled human malaria infection study. Lancet Microbe 0, 100867 (2024).","journal-title":"Lancet Microbe"},{"key":"4107_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0035-9203(91)90012-N","volume":"85","author":"T Ponnudurai","year":"1991","unstructured":"Ponnudurai, T., Lensen, A. H. W., Gemert, G. J. A., Bolmer, M. G. & Meuwissen, J. H. T. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans. R. Soc. Trop. Med. Hyg. 85, 175\u2013180 (1991).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"4107_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe, S. et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 91, 471\u2013480 (2014).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"4107_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller, B. et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar. J. 14, 117 (2015).","journal-title":"Malar. J."},{"key":"4107_CR18","doi-asserted-by":"publisher","first-page":"e07789","DOI":"10.7554\/eLife.07789","volume":"4","author":"CS Hopp","year":"2015","unstructured":"Hopp, C. S. et al. Longitudinal analysis of Plasmodium sporozoite motility in the dermis reveals component of blood vessel recognition. Elife 4, e07789 (2015).","journal-title":"Elife"},{"key":"4107_CR19","doi-asserted-by":"publisher","first-page":"02194","DOI":"10.1128\/mBio.02194-18","volume":"9","author":"Y Flores-Garcia","year":"2018","unstructured":"Flores-Garcia, Y. et al. Antibody-mediated protection against Plasmodium sporozoites begins at the dermal inoculation site. mBio 9, 02194\u201318 (2018).","journal-title":"mBio"},{"key":"4107_CR20","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41564-018-0254-z","volume":"3","author":"E Aliprandini","year":"2018","unstructured":"Aliprandini, E. et al. Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin. Nat. Microbiol 3, 1224\u20131233 (2018).","journal-title":"Nat. Microbiol"},{"key":"4107_CR21","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/mt.2014.109","volume":"22","author":"D Kimani","year":"2014","unstructured":"Kimani, D. et al. Translating the Immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol. Ther. 22, 1992\u20132003 (2014).","journal-title":"Mol. Ther."},{"key":"4107_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","volume":"211","author":"SH Hodgson","year":"2015","unstructured":"Hodgson, S. H. et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211, 1076\u20131086 (2015).","journal-title":"J. Infect. Dis."},{"key":"4107_CR23","doi-asserted-by":"publisher","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","volume":"13","author":"AB Tiono","year":"2018","unstructured":"Tiono, A. B. et al. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5\u201317 months old infants and children. PLoS ONE 13, e0208328 (2018).","journal-title":"PLoS ONE"},{"key":"4107_CR24","doi-asserted-by":"publisher","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","volume":"7","author":"C Ogwang","year":"2015","unstructured":"Ogwang, C. et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7, 286re5 (2015).","journal-title":"Sci Transl Med"},{"key":"4107_CR25","doi-asserted-by":"publisher","first-page":"1672945","DOI":"10.3389\/fimmu.2025.1672945","volume":"16","author":"R Ogwang","year":"2025","unstructured":"Ogwang, R., Adan, M., Bejon, P. & Kapulu, M. C. Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons. Front. Immunol. 16, 1672945 (2025).","journal-title":"Front. Immunol."},{"key":"4107_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.12688\/wellcomeopenres.14439.1","volume":"3","author":"M Njue","year":"2018","unstructured":"Njue, M. et al. Ethical considerations in controlled human malaria infection studies in low resource settings: experiences and perceptions of study participants in a malaria challenge study in Kenya. Wellcome Open Res. 3, 39 (2018).","journal-title":"Wellcome Open Res."},{"key":"4107_CR27","doi-asserted-by":"publisher","first-page":"e146443","DOI":"10.1172\/jci.insight.146443","volume":"6","author":"MC Kapulu","year":"2021","unstructured":"Kapulu, M. C. et al. Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. JCI Insight 6, e146443 (2021).","journal-title":"JCI Insight"},{"key":"4107_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu, A. et al. Four-year efficacy of RTS,S\/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111\u20131120 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by v\u00ffaccination. Clin. Vaccine Immunol. 17, 1055 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"4107_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S1473-3099(23)00131-7","volume":"23","author":"A Juan-Giner","year":"2023","unstructured":"Juan-Giner, A. et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect. Dis. 23, 965\u2013973 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"4107_CR31","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMoa2314620","volume":"391","author":"KE Gallagher","year":"2024","unstructured":"Gallagher, K. E. et al. Fractional doses of pneumococcal conjugate vaccine\u2014a noninferiority Trial. N. Engl. J. Med. 391, 2003\u20132013 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR32","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","volume":"364","author":"SO Sow","year":"2011","unstructured":"Sow, S. O. et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N. Engl. J. Med. 364, 2293\u20132304 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4107_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(05)67568-X","volume":"366","author":"AR Zanetti","year":"2005","unstructured":"Zanetti, A. R. et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366, 1379\u20131384 (2005).","journal-title":"Lancet"},{"key":"4107_CR34","doi-asserted-by":"publisher","first-page":"112681","DOI":"10.1016\/j.celrep.2023.112681","volume":"42","author":"MC Aguirre-Botero","year":"2023","unstructured":"Aguirre-Botero, M. C. et al. Cytotoxicity of human antibodies targeting the circumsporozoite protein is amplified by 3D substrate and correlates with protection. Cell Rep. 42, 112681 (2023).","journal-title":"Cell Rep."},{"key":"4107_CR35","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1126\/science.1704150","volume":"251","author":"Y Charoenvit","year":"1991","unstructured":"Charoenvit, Y. et al. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251, 668\u2013671 (1991).","journal-title":"Science"},{"key":"4107_CR36","doi-asserted-by":"publisher","unstructured":"Roozen, G. V. T. et al. Single immunization with genetically attenuated Pf\u2206mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03347-2 (2025).","DOI":"10.1038\/s41591-024-03347-2"},{"key":"4107_CR37","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.4049\/jimmunol.179.6.4193","volume":"179","author":"P Bejon","year":"2007","unstructured":"Bejon, P. et al. The induction and persistence of T cell IFN-\u03b3 responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J. Immunol. 179, 4193\u20134201 (2007).","journal-title":"J. Immunol."},{"key":"4107_CR38","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/mt.2014.109","volume":"22","author":"D Kimani","year":"2014","unstructured":"Kimani, D. et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA METRAP from malaria naive to malaria-endemic populations. Mol. Ther. 22, 1992\u20132003 (2014).","journal-title":"Mol. Ther."},{"key":"4107_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4269\/ajtmh.2008.79.185","volume":"79","author":"WP O\u2019Meara","year":"2008","unstructured":"O\u2019Meara, W. P. et al. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am. J. Trop. Med. Hyg. 79, 185 (2008).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"4107_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12879-022-07044-8","volume":"22","author":"MC Kapulu","year":"2022","unstructured":"Kapulu, M. C. et al. Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response. BMC Infect. Dis. 22, 86 (2022).","journal-title":"BMC Infect. Dis."},{"key":"4107_CR41","doi-asserted-by":"crossref","unstructured":"Sang, S. et al. Safety and immunogenicity of varied doses of R21\/Matrix-MTM vaccine at three years follow-up: a phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya. Wellcome Open Res. 8, 450 (2023).","DOI":"10.12688\/wellcomeopenres.19795.1"},{"key":"4107_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmala.2025.1497613","volume":"3","author":"E Kibwana","year":"2025","unstructured":"Kibwana, E. et al. Quantification of Plasmodium falciparum: validation of quantitative polymerase chain reaction assays for detection of parasites in controlled human malaria infection studies. Front. Malar. 3, 1497613 (2025).","journal-title":"Front. Malar."},{"key":"4107_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.12688\/wellcomeopenres.17736.4","volume":"7","author":"K Wamae","year":"2024","unstructured":"Wamae, K. et al. Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial. Wellcome Open Res. 7, 95 (2024).","journal-title":"Wellcome Open Res."},{"key":"4107_CR44","unstructured":"Kapulu, M. C et al. Replication data for: The malaria vaccine R21 is protective against intradermal but not intravenous Plasmodium falciparum sporozoites in controlled human malaria infection in Kenyan adults Biosciences Dataverse https:\/\/dataverse.harvard.edu\/dataset.xhtml?persistentId=doi:10.7910\/DVN\/TNHS14 (2025)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04107-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:03:13Z","timestamp":1769007793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04107-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V.S.H. and K.J.E. are named as co-inventors on patent applications related to R21\/MM. K.J.E. was an employee of the University of Oxford at the time of the work and is now an employee of GSK and owns restricted shares in GSK. A.V.S.H. is a co-inventor of the R21\/MM vaccine and chief investigator of the published phase III trial, and may derive some royalties from vaccine sales in keeping with the University of Oxford\u2019s royalty sharing arrangements. Y.A., E.R.J., P.F.B., T.L.R., B.K.L.S and S.L.H. are salaried, full-time employees of Sanaria, the manufacturer of Sanaria PfSPZ Challenge. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}